TARO / Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Taro (TARO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). more_horizontal

Taro received a $38/share offer from Sun Pharma last month. The deal represents a decent premium to the firm's market value at the time and a 12% prem more_horizontal

Taro saw rising revenue in the fourth quarter but falling net income. Sun Pharmaceutical already owns 78.5% of Taro's shares. more_horizontal

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for more_horizontal

Taro Pharmaceutical's quarterly numbers came in with very thin growth at the operating and bottom-lines given the impact from settlement charges. Pric more_horizontal

Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clu more_horizontal

HAWTHORNE, N.Y.--( BUSINESS WIRE )--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results fo more_horizontal

Taro (TARO) delivered earnings and revenue surprises of -56.47% and 4.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to more_horizontal